| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 41, 1592-1598, Copyright © 1995 by American Association for Clinical Chemistry
A Blumsohn, KE Naylor, AM Assiri and R Eastell
Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, UK.
We examined the response of different biochemical markers of bone resorption to bisphosphonate therapy (400 mg of etidronate daily for 6 months) in mild Paget disease (n = 14). Urinary markers included hydroxyproline (OHP), total (T) and free (F) pyridinolines (Pyds) determined by HPLC, immunoreactive FPyds, immunoreactive TPyds, and the N- and C-terminal telopeptides of type I collage (NTx, CL). Serum measurements included tartrate-resistant acid phosphatase (TRAcP) and the C-terminal telopeptide of type I collagen (ICTP). ICTP and TRAcP showed a minimal response to therapy (% change at 6 months, -13.1 +/- 6.8 and -6.7 +/- 3.4, respectively). The response was greatest for urinary telopeptides (NTx and CL; % change -75.7 +/- 7.5 and -73.4 +/- 8.9, respectively). The response was somewhat greater for TPyds than for FPyds. We conclude that: (a) ICTP and TRAcP are unreliable indicators of changes in bone turnover; (b) oligopeptide-bound Pyds and telopeptide fragments of type I collagen in urine show a somewhat greater response to therapy than do FPyds and may be more sensitive indicators of bone resorption; and (c) as yet no evidence suggests that these markers are substantially better predictors of the clinical response to therapy than serum total alkaline phosphatase or urinary OHP. There are several problems with the interpretation of these measurements in Paget disease, and the clinical utility of these measurements remains uncertain.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  H. W. Vesper, L. M. Demers, R. Eastell, P. Garnero, M. Kleerekoper, S. P. Robins, A. K. Srivastava, G. R. Warnick, N. B. Watts, and G. L. Myers Assessment and Recommendations on Factors Contributing to Preanalytical Variability of Urinary Pyridinoline and Deoxypyridinoline Clin. Chem., February 1, 2002; 48(2): 220 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Heuck, L. Heickendorff, and O. D Wolthers A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide Arch. Dis. Child., October 1, 2000; 83(4): 334 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rubinacci, R. Melzi, M. Zampino, A. Soldarini, and I. Villa Total and Free Deoxypyridinoline after Acute Osteoclast Activity Inhibition Clin. Chem., September 1, 1999; 45(9): 1510 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Berruti, L. Dogliotti, G. Gorzegno, M. Torta, M. Tampellini, M. Tucci, S. Cerutti, M. Mosca Frezet, M. Stivanello, G. Sacchetto, et al. Differential Patterns of Bone Turnover in Relation to Bone Pain and Disease Extent in Bone in Cancer Patients with Skeletal Metastases Clin. Chem., August 1, 1999; 45(8): 1240 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Al-Dehaimi, A. Blumsohn, and R. Eastell Serum Galactosyl Hydroxylysine as a Biochemical Marker of Bone Resorption Clin. Chem., May 1, 1999; 45(5): 676 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rosenquist, C. Fledelius, S. Christgau, B. J. Pedersen, M. Bonde, P. Qvist, and C. Christiansen Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen Clin. Chem., November 1, 1998; 44(11): 2281 - 2289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Christgau, C. Rosenquist, P. Alexandersen, N. H. Bjarnason, P. Ravn, C. Fledelius, C. Herling, P. Qvist, and C. Christiansen Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides Clin. Chem., November 1, 1998; 44(11): 2290 - 2300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kamel, P. Fardellone, B. Meddah, F. Lorget-Gondelmann, J. L. Sebert, and M. Brazier Response of several markers of bone collagen degradation to calcium supplementation in postmenopausal women with low calcium intake Clin. Chem., July 1, 1998; 44(7): 1437 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Clemens, M. V. Herrick, F. R. Singer, and D. R. Eyre Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption Clin. Chem., November 1, 1997; 43(11): 2058 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zanze, J. C. Souberbielle, C. Kindermans, C. Rossignol, and M. Garabedian Procollagen Propeptide and Pyridinium Cross-Links as Markers of Type I Collagen Turnover: Sex- and Age-Related Changes in Healthy Children J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2971 - 2977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-S. J. Ju, S. Leung, B. Brown, M. A. Stringer, S. Leigh, C. Scherrer, K. Shepard, D. Jenkins, J. Knudsen, and R. Cannon Comparison of analytical performance and biological variability of three bone resorption assays Clin. Chem., September 1, 1997; 43(9): 1570 - 1576. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
